Clinical trials in Groningen – page 3

557 clinical trials in Groningen, The Netherlands across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Groningen at a glance

557

clinical trials

Research sites8

Quick filters

557 trials in Groningen

Open in trial search

Osteosarcoma

Recruiting

Registered drugNo placebo

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Institut Gustave Roussy

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Gastric cancer+1

Recruiting

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Azd0901
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Recruiting

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Factor VIII deficiency

Recruiting

Registered drugNo placebo

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emicizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Non-small cell lung cancer stage III

Recruiting

Registered drugNo placebo

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Colorectal cancer metastatic

Recruiting

Registered drug

INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Incyte Corp.

Contact Research Centre

Coagulation factor X level

Recruiting

InvestigationalNo placebo

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:VMX-C001
Sponsor:VarmX B.V.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

InvestigationalNo placebo

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Janssen Cilag International

Contact Research Centre

Neuroendocrine carcinoma

Recruiting

Registered drugNo placebo

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Cervix carcinoma

Recruiting

Registered drugNo placebo

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Fallopian tube cancer+2

Recruiting

Registered drugNo placebo

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Groningen

What the registry says about research in the country

01 Cardiovascular Research

Advanced studies focusing on heart disease and cardiovascular conditions, including innovative treatments for ATTR amyloidosis and prevention strategies for heart failure.

Cardiomyopathy Treatments
Heart Failure Prevention
Peripheral Arterial Disease

Multiple trials exploring novel therapeutic approaches and preventive measures for various cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including melanoma and lung cancer, with particular focus on innovative treatment approaches and metastatic disease management.

Advanced Breast Cancer
Small Cell Lung Cancer
Brain Metastases

Investigation of targeted therapies and combination treatments for improved patient outcomes.

03 Metabolic Disorders

Clinical investigations focusing on obesity and type 2 diabetes, testing new therapeutic approaches for weight management and metabolic control.

Weight Management
Diabetes Treatment
Metabolic Health

Evaluation of novel medications combined with lifestyle interventions for optimal patient care.

Back to the Netherlands All countries